<DOC>
	<DOC>NCT00628758</DOC>
	<brief_summary>The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adult patients with persistent asthma.</brief_summary>
	<brief_title>A Comparison of SymbicortÂ® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma</brief_title>
	<detailed_description>A secondary objective is to collect safety data for treatment wtih Symbicort Single inhaler Therapy in adult patients with persistent asthma.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Signed informed consent form. If the patient cannot read and write, verbal consent from the patient is required. Ability to read and write in Turkish Female or male outpatients aged 18 years Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition Prescribed inhaled glucocorticosteroid (GCS) at a dose of 320mg/day and within the approved label for the relevant drug during the last 3 months prior to Visit 1 Either: daily maintenance treatment with both inhaled GCS and longacting b2agonist (LABA) or daily treatment with inhaled GCS alone (i.e. without LABA); and a history of suboptimal asthma control the month prior to enrollment as judged by the investigator; and use of 3 Peak Expiratory Flow inhalations ofas needed medication for symptom relief during the last 7 days before enrollment Previous treatment with Symbicort Single inhaler Therapy Use of any bblocking agent, including eye drops Use of oral GCS as maintenance treatment Known or suspected hypersensitivity to study therapy or excipients A history of smoking 10 pack years Pregnancy, breastfeeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator Any significant disease or disorder, which, in the opinion of the investigator, may put the patient at risk because of participating in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Symbicort</keyword>
	<keyword>Turbuhaler</keyword>
	<keyword>Persistent Asthma</keyword>
</DOC>